

CLAIMS

1. A pharmaceutical combination comprising (i) firobostat, (ii) a diuretic and (iii) a blocker of the systemic renin-angiotensin system selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type 1 antagonists, for use in the treatment of arterial hypertension or indirectly or directly related diseases, especially heart failure.

2. The pharmaceutical combination according to claim 1, wherein the diuretic is selected from the group consisting of chlorothiazide, hydrochlorothiazide, chlorthalidone, indapamide, furosemide, torsemide, amiloride, triamterene, spironolactone and eplerenone, more preferably the diuretic is selected from the group consisting of hydrochlorothiazide, chlorthalidone, indapamide, and amiloride.

3. The pharmaceutical combination according to claim 1 or 2, wherein the diuretic is hydrochlorothiazide.

4. The pharmaceutical combination according to any one of the preceding claims, wherein the blocker of the systemic renin-angiotensin system is selected from the group of angiotensin converting enzyme inhibitors consisting of lisinopril, enalapril, quinapril, ramipril, benazepril, captopril, cilazapril, fosinopril, imidapril, moexipril, trandolapril, or perindopril, more preferably the angiotensin converting enzyme inhibitor is selected from the group consisting of enalapril, perindopril, ramipril, lisinopril and benazepril.

5. The pharmaceutical combination according to any one of the preceding claims, wherein the blocker of the systemic renin-angiotensin system is enalapril.

6. The pharmaceutical combination according to any one of the claims 1 to 3, wherein the blocker of the systemic renin-angiotensin system is selected from the group consisting of angiotensin II receptor type 1 antagonists consisting of losartan, candesartan, irbesartan, telmisartan, valsartan, olmesartan,

eprosartan and azilsartan, more preferably selected from the group consisting of losartan, valsartan, candesartan, irbesartan, and azilsartan.

7. The pharmaceutical combination according to any one of the claims 1
5 to 3, or Claim 6, wherein the blocker of the systemic renin-angiotensin system is valsartan.

8. The pharmaceutical combination according to claim 1, wherein the
10 diuretic is hydrochlorothiazide and the blocker of the systemic renin-angiotensin system is enalapril.

9. The pharmaceutical combination according to claim 1, wherein the
diuretic is hydrochlorothiazide and the blocker of the systemic renin-angiotensin
system is valsartan.
15

10. The pharmaceutical combination according to claim 1, wherein the
diuretic is indapamide and the blocker of the systemic renin-angiotensin system
is perindopril.

20 11. The pharmaceutical combination according to claim 1, wherein the
diuretic is chlorthalidone and the blocker of the systemic renin-angiotensin
system is azilsartan.

12. The pharmaceutical combination according to claim 8, containing
25 firibastat in an amount in the range from 100 to 1500 mg, hydrochlorothiazide in
an amount in the range from 5 to 30 mg, and enalapril in an amount in the range
from 2.5 to 50 mg.

13. The pharmaceutical combination according to claim 8, containing
30 firibastat in an amount in the range from 300 to 600 mg, hydrochlorothiazide in
an amount in the range from 5 to 15 mg, and enalapril in an amount in the range
from 2.5 to 15 mg.

14. The pharmaceutical combination according to any one of claims 1-13, wherein the three active ingredients are administered simultaneously or sequentially, preferably simultaneously administered.

5

15. A kit of parts comprising a pharmaceutical combination containing (i) firibastat, (ii) a diuretic, (iii) a blocker of the systemic renin-angiotensin system selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type 1 antagonists, in the form of one, two or three
10 separate units of the components (i) to (iii), for a simultaneous or sequential administration, preferably for simultaneous administration.

16. The kit according to claim 15, wherein (ii) the diuretic is selected from the group consisting of hydrochlorothiazide, indapamide, amiloride and
15 chlorthalidone, and (iii) the blocker of the systemic renin-angiotensin system is selected from the group consisting of angiotensin I converting enzyme inhibitors consisting of enalapril, perindopril, ramipril and benazepril or from angiotensin II receptor type 1 antagonists the group consisting of losartan, valsartan, candesartan, irbesartan and azilsartan.

20

17. The kit according to claim 15, wherein (ii) the diuretic is hydrochlorothiazide and (iii) the blocker of the systemic renin-angiotensin system is enalapril.

25 18. The kit according to claim 15, wherein (ii) the diuretic is hydrochlorothiazide and (iii) the blocker of the systemic renin-angiotensin system is valsartan.

19. The kit according to claim 15, wherein (ii) the diuretic is indapamide
30 and (iii) the blocker of the systemic renin-angiotensin system is perindopril.

20. The kit according to claim 15, wherein (ii) the diuretic is chlorthalidone and (iii) the blocker of the systemic renin-angiotensin system is azilsartan.
- 5 21. The kit according to any one of claims 15-20, which is suitable for the treatment of hypertension and related diseases and conditions.